AstraZeneca PLC (NYSE: AZN) Stock Competitors & Peer Comparison
See AZN's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for AZN and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| AZN | $161.42 | +0.88% | 250.3B | 17.43 | $9.26 | +1.30% |
| LLY | $1,185.71 | -0.52% | 1.1T | 37.64 | $31.49 | +0.55% |
| JNJ | $259.24 | +0.88% | 624.7B | 24.16 | $10.73 | +2.04% |
| ABBV | $246.04 | +0.89% | 434.4B | 24.13 | $10.19 | +2.79% |
| MRK | $128.57 | +0.16% | 317.5B | 40.05 | $3.21 | +2.61% |
| NVS | $156.33 | +1.37% | 297.2B | 17.99 | $8.69 | +3.03% |
| AMGN | $410.95 | +1.51% | 221.8B | 18.37 | $22.37 | +2.39% |
| NVO | $47.26 | +2.81% | 209.8B | 11.75 | $4.02 | +3.82% |
| GILD | $133.21 | +1.80% | 165.4B | -341.56 | -$0.39 | +2.42% |
| PFE | $26.76 | +2.14% | 152.4B | 8.77 | $3.05 | +6.47% |
Stock Comparison
Eli Lilly and Company (NYSE: LLY)
AZN vs LLY Comparison August 2026
AstraZeneca PLC (NYSE: AZN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AZN stands at 250.3B. In comparison, LLY has a market cap of 1.1T. Regarding current trading prices, AZN is priced at $161.42 on the NYSE, while LLY trades at $1,185.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AZN currently has a P/E ratio of 17.43, whereas LLY's P/E ratio is 37.64. In terms of profitability, AZN's ROE is +0.22%, compared to LLY's ROE of +0.93%. Regarding short-term risk, AZN is less volatile compared to LLY. This indicates lower risk in terms of short-term price fluctuations for AZN.Check LLY's competition here
Johnson & Johnson (NYSE: JNJ)
AZN vs JNJ Comparison August 2026
AstraZeneca PLC (NYSE: AZN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AZN stands at 250.3B. In comparison, JNJ has a market cap of 624.7B. Regarding current trading prices, AZN is priced at $161.42 on the NYSE, while JNJ trades at $259.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AZN currently has a P/E ratio of 17.43, whereas JNJ's P/E ratio is 24.16. In terms of profitability, AZN's ROE is +0.22%, compared to JNJ's ROE of +0.26%. Regarding short-term risk, AZN is less volatile compared to JNJ. This indicates lower risk in terms of short-term price fluctuations for AZN.Check JNJ's competition here
AbbVie Inc. (NYSE: ABBV)
AZN vs ABBV Comparison August 2026
AstraZeneca PLC (NYSE: AZN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AZN stands at 250.3B. In comparison, ABBV has a market cap of 434.4B. Regarding current trading prices, AZN is priced at $161.42 on the NYSE, while ABBV trades at $246.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AZN currently has a P/E ratio of 17.43, whereas ABBV's P/E ratio is 24.13. In terms of profitability, AZN's ROE is +0.22%, compared to ABBV's ROE of -1.37%. Regarding short-term risk, AZN is less volatile compared to ABBV. This indicates lower risk in terms of short-term price fluctuations for AZN.Check ABBV's competition here
Merck & Co., Inc. (NYSE: MRK)
AZN vs MRK Comparison August 2026
AstraZeneca PLC (NYSE: AZN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AZN stands at 250.3B. In comparison, MRK has a market cap of 317.5B. Regarding current trading prices, AZN is priced at $161.42 on the NYSE, while MRK trades at $128.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AZN currently has a P/E ratio of 17.43, whereas MRK's P/E ratio is 40.05. In terms of profitability, AZN's ROE is +0.22%, compared to MRK's ROE of +0.18%. Regarding short-term risk, AZN is less volatile compared to MRK. This indicates lower risk in terms of short-term price fluctuations for AZN.Check MRK's competition here
Novartis AG (NYSE: NVS)
AZN vs NVS Comparison August 2026
AstraZeneca PLC (NYSE: AZN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AZN stands at 250.3B. In comparison, NVS has a market cap of 297.2B. Regarding current trading prices, AZN is priced at $161.42 on the NYSE, while NVS trades at $156.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AZN currently has a P/E ratio of 17.43, whereas NVS's P/E ratio is 17.99. In terms of profitability, AZN's ROE is +0.22%, compared to NVS's ROE of +0.30%. Regarding short-term risk, AZN is more volatile compared to NVS. This indicates higher risk in terms of short-term price fluctuations for AZN.Check NVS's competition here
Amgen Inc. (NASDAQ: AMGN)
AZN vs AMGN Comparison August 2026
AstraZeneca PLC (NYSE: AZN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AZN stands at 250.3B. In comparison, AMGN has a market cap of 221.8B. Regarding current trading prices, AZN is priced at $161.42 on the NYSE, while AMGN trades at $410.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AZN currently has a P/E ratio of 17.43, whereas AMGN's P/E ratio is 18.37. In terms of profitability, AZN's ROE is +0.22%, compared to AMGN's ROE of +0.89%. Regarding short-term risk, AZN is less volatile compared to AMGN. This indicates lower risk in terms of short-term price fluctuations for AZN.Check AMGN's competition here
Novo Nordisk A/S (NYSE: NVO)
AZN vs NVO Comparison August 2026
AstraZeneca PLC (NYSE: AZN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AZN stands at 250.3B. In comparison, NVO has a market cap of 209.8B. Regarding current trading prices, AZN is priced at $161.42 on the NYSE, while NVO trades at $47.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AZN currently has a P/E ratio of 17.43, whereas NVO's P/E ratio is 11.75. In terms of profitability, AZN's ROE is +0.22%, compared to NVO's ROE of +0.59%. Regarding short-term risk, AZN is less volatile compared to NVO. This indicates lower risk in terms of short-term price fluctuations for AZN.Check NVO's competition here
Gilead Sciences, Inc. (NASDAQ: GILD)
AZN vs GILD Comparison August 2026
AstraZeneca PLC (NYSE: AZN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AZN stands at 250.3B. In comparison, GILD has a market cap of 165.4B. Regarding current trading prices, AZN is priced at $161.42 on the NYSE, while GILD trades at $133.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AZN currently has a P/E ratio of 17.43, whereas GILD's P/E ratio is -341.56. In terms of profitability, AZN's ROE is +0.22%, compared to GILD's ROE of -0.16%. Regarding short-term risk, AZN is less volatile compared to GILD. This indicates lower risk in terms of short-term price fluctuations for AZN.Check GILD's competition here
Pfizer Inc. (NYSE: PFE)
AZN vs PFE Comparison August 2026
AstraZeneca PLC (NYSE: AZN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AZN stands at 250.3B. In comparison, PFE has a market cap of 152.4B. Regarding current trading prices, AZN is priced at $161.42 on the NYSE, while PFE trades at $26.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AZN currently has a P/E ratio of 17.43, whereas PFE's P/E ratio is 8.77. In terms of profitability, AZN's ROE is +0.22%, compared to PFE's ROE of +0.05%. Regarding short-term risk, AZN is less volatile compared to PFE. This indicates lower risk in terms of short-term price fluctuations for AZN.Check PFE's competition here
Bristol-Myers Squibb Company (NYSE: BMY)
AZN vs BMY Comparison August 2026
AstraZeneca PLC (NYSE: AZN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AZN stands at 250.3B. In comparison, BMY has a market cap of 132.2B. Regarding current trading prices, AZN is priced at $161.42 on the NYSE, while BMY trades at $64.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AZN currently has a P/E ratio of 17.43, whereas BMY's P/E ratio is 10.91. In terms of profitability, AZN's ROE is +0.22%, compared to BMY's ROE of +0.47%. Regarding short-term risk, AZN is less volatile compared to BMY. This indicates lower risk in terms of short-term price fluctuations for AZN.Check BMY's competition here
GSK plc (NYSE: GSK)
AZN vs GSK Comparison August 2026
AstraZeneca PLC (NYSE: AZN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AZN stands at 250.3B. In comparison, GSK has a market cap of 106.1B. Regarding current trading prices, AZN is priced at $161.42 on the NYSE, while GSK trades at $52.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AZN currently has a P/E ratio of 17.43, whereas GSK's P/E ratio is 11.44. In terms of profitability, AZN's ROE is +0.22%, compared to GSK's ROE of +0.24%. Regarding short-term risk, AZN is more volatile compared to GSK. This indicates higher risk in terms of short-term price fluctuations for AZN.Check GSK's competition here
Sanofi (NASDAQ: SNY)
AZN vs SNY Comparison August 2026
AstraZeneca PLC (NYSE: AZN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AZN stands at 250.3B. In comparison, SNY has a market cap of 104.4B. Regarding current trading prices, AZN is priced at $161.42 on the NYSE, while SNY trades at $43.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AZN currently has a P/E ratio of 17.43, whereas SNY's P/E ratio is 9.47. In terms of profitability, AZN's ROE is +0.22%, compared to SNY's ROE of +0.06%. Regarding short-term risk, AZN is more volatile compared to SNY. This indicates higher risk in terms of short-term price fluctuations for AZN.Check SNY's competition here
Biogen Inc. (NASDAQ: BIIB)
AZN vs BIIB Comparison August 2026
AstraZeneca PLC (NYSE: AZN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AZN stands at 250.3B. In comparison, BIIB has a market cap of 30.7B. Regarding current trading prices, AZN is priced at $161.42 on the NYSE, while BIIB trades at $207.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AZN currently has a P/E ratio of 17.43, whereas BIIB's P/E ratio is 13.13. In terms of profitability, AZN's ROE is +0.22%, compared to BIIB's ROE of +0.05%. Regarding short-term risk, AZN is less volatile compared to BIIB. This indicates lower risk in terms of short-term price fluctuations for AZN.Check BIIB's competition here
Zoetis Inc. (NYSE: ZTS)
AZN vs ZTS Comparison August 2026
AstraZeneca PLC (NYSE: AZN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AZN stands at 250.3B. In comparison, ZTS has a market cap of 30.5B. Regarding current trading prices, AZN is priced at $161.42 on the NYSE, while ZTS trades at $72.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AZN currently has a P/E ratio of 17.43, whereas ZTS's P/E ratio is 11.04. In terms of profitability, AZN's ROE is +0.22%, compared to ZTS's ROE of +0.69%. Regarding short-term risk, AZN is less volatile compared to ZTS. This indicates lower risk in terms of short-term price fluctuations for AZN.Check ZTS's competition here
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP)
AZN vs HZNP Comparison August 2026
AstraZeneca PLC (NYSE: AZN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AZN stands at 250.3B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, AZN is priced at $161.42 on the NYSE, while HZNP trades at $116.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AZN currently has a P/E ratio of 17.43, whereas HZNP's P/E ratio is 61.86. In terms of profitability, AZN's ROE is +0.22%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, AZN is more volatile compared to HZNP. This indicates higher risk in terms of short-term price fluctuations for AZN.Check HZNP's competition here
Grifols, S.A. (NASDAQ: GRFS)
AZN vs GRFS Comparison August 2026
AstraZeneca PLC (NYSE: AZN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AZN stands at 250.3B. In comparison, GRFS has a market cap of 6.7B. Regarding current trading prices, AZN is priced at $161.42 on the NYSE, while GRFS trades at $7.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AZN currently has a P/E ratio of 17.43, whereas GRFS's P/E ratio is 9.12. In terms of profitability, AZN's ROE is +0.22%, compared to GRFS's ROE of +0.08%. Regarding short-term risk, AZN is less volatile compared to GRFS. This indicates lower risk in terms of short-term price fluctuations for AZN.Check GRFS's competition here
Organon & Co. (NYSE: OGN)
AZN vs OGN Comparison August 2026
AstraZeneca PLC (NYSE: AZN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AZN stands at 250.3B. In comparison, OGN has a market cap of 3.6B. Regarding current trading prices, AZN is priced at $161.42 on the NYSE, while OGN trades at $13.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AZN currently has a P/E ratio of 17.43, whereas OGN's P/E ratio is 4.06. In terms of profitability, AZN's ROE is +0.22%, compared to OGN's ROE of +0.23%. Regarding short-term risk, AZN is more volatile compared to OGN. This indicates higher risk in terms of short-term price fluctuations for AZN.Check OGN's competition here
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI)
AZN vs CELG-RI Comparison August 2026
AstraZeneca PLC (NYSE: AZN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AZN stands at 250.3B. In comparison, CELG-RI has a market cap of 224.5M. Regarding current trading prices, AZN is priced at $161.42 on the NYSE, while CELG-RI trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AZN currently has a P/E ratio of 17.43, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, AZN's ROE is +0.22%, compared to CELG-RI's ROE of N/A. Regarding short-term risk, AZN is less volatile compared to CELG-RI. This indicates lower risk in terms of short-term price fluctuations for AZN.Check CELG-RI's competition here
Citius Oncology, Inc. (NASDAQ: CTOR)
AZN vs CTOR Comparison August 2026
AstraZeneca PLC (NYSE: AZN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AZN stands at 250.3B. In comparison, CTOR has a market cap of 72.5M. Regarding current trading prices, AZN is priced at $161.42 on the NYSE, while CTOR trades at $0.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AZN currently has a P/E ratio of 17.43, whereas CTOR's P/E ratio is -1.66. In terms of profitability, AZN's ROE is +0.22%, compared to CTOR's ROE of -0.99%. Regarding short-term risk, AZN is less volatile compared to CTOR. This indicates lower risk in terms of short-term price fluctuations for AZN.Check CTOR's competition here
Scilex Holding Company (NASDAQ: SCLX)
AZN vs SCLX Comparison August 2026
AstraZeneca PLC (NYSE: AZN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AZN stands at 250.3B. In comparison, SCLX has a market cap of 59M. Regarding current trading prices, AZN is priced at $161.42 on the NYSE, while SCLX trades at $6.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AZN currently has a P/E ratio of 17.43, whereas SCLX's P/E ratio is -0.18. In terms of profitability, AZN's ROE is +0.22%, compared to SCLX's ROE of +1.90%. Regarding short-term risk, AZN is less volatile compared to SCLX. This indicates lower risk in terms of short-term price fluctuations for AZN.Check SCLX's competition here
Scilex Holding Company (NASDAQ: SCLXW)
AZN vs SCLXW Comparison August 2026
AstraZeneca PLC (NYSE: AZN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AZN stands at 250.3B. In comparison, SCLXW has a market cap of 58.9M. Regarding current trading prices, AZN is priced at $161.42 on the NYSE, while SCLXW trades at $0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AZN currently has a P/E ratio of 17.43, whereas SCLXW's P/E ratio is -0.01. In terms of profitability, AZN's ROE is +0.22%, compared to SCLXW's ROE of +1.90%. Regarding short-term risk, AZN is less volatile compared to SCLXW. This indicates lower risk in terms of short-term price fluctuations for AZN.Check SCLXW's competition here
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA)
AZN vs MIRA Comparison August 2026
AstraZeneca PLC (NYSE: AZN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AZN stands at 250.3B. In comparison, MIRA has a market cap of 31.1M. Regarding current trading prices, AZN is priced at $161.42 on the NYSE, while MIRA trades at $0.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AZN currently has a P/E ratio of 17.43, whereas MIRA's P/E ratio is -0.51. In terms of profitability, AZN's ROE is +0.22%, compared to MIRA's ROE of -1.41%. Regarding short-term risk, AZN is less volatile compared to MIRA. This indicates lower risk in terms of short-term price fluctuations for AZN.Check MIRA's competition here
BioDelivery Sciences Intl, Inc. Wrrt (NASDAQ: BDSIW)
AZN vs BDSIW Comparison August 2026
AstraZeneca PLC (NYSE: AZN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AZN stands at 250.3B. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, AZN is priced at $161.42 on the NYSE, while BDSIW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AZN currently has a P/E ratio of 17.43, whereas BDSIW's P/E ratio is -0.43. In terms of profitability, AZN's ROE is +0.22%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, AZN is less volatile compared to BDSIW. This indicates lower risk in terms of short-term price fluctuations for AZN.Check BDSIW's competition here
Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT)
AZN vs CRXT Comparison August 2026
AstraZeneca PLC (NYSE: AZN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AZN stands at 250.3B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, AZN is priced at $161.42 on the NYSE, while CRXT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AZN currently has a P/E ratio of 17.43, whereas CRXT's P/E ratio is -0.02. In terms of profitability, AZN's ROE is +0.22%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, AZN is less volatile compared to CRXT. This indicates lower risk in terms of short-term price fluctuations for AZN.Check CRXT's competition here